| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 35, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 16:20

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 35, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Date of authorisation: 23/03/2015, Revision: 26, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 16:02

Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Date of authorisation: 23/03/2015, Revision: 26, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Date of authorisation: 23/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 16, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 15:52

Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 16, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 49, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 15:44

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 49, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Bexsero, meningococcal group B Vaccine (rDNA, component, adsorbed), Date of authorisation: 13/01/2013, Revision: 37, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 15:28

Human medicines European public assessment report (EPAR): Bexsero, meningococcal group B Vaccine (rDNA, component, adsorbed), Date of authorisation: 13/01/2013, Revision: 37, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Bexsero, meningococcal group B Vaccine (rDNA, component, adsorbed), Date of authorisation: 13/01/2013, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Date of authorisation: 15/07/2026, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 14:35

Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Date of authorisation: 15/07/2026, Revision: 1, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Date of authorisation: 15/07/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 14:28

Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 14:08

Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 5, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Rezolsta, darunavir,cobicistat, Date of authorisation: 19/11/2014, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 13:47

Human medicines European public assessment report (EPAR): Rezolsta, darunavir,cobicistat, Date of authorisation: 19/11/2014, Revision: 20, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Rezolsta, darunavir,cobicistat, Date of authorisation: 19/11/2014, Revision: 20, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Date of authorisation: 23/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Date of authorisation: 22/01/2007, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Bexsero, meningococcal group B Vaccine (rDNA, component, adsorbed), Date of authorisation: 13/01/2013, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Vislyfa, ranibizumab, Date of authorisation: 15/07/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Rezolsta, darunavir,cobicistat, Date of authorisation: 19/11/2014, Revision: 20, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters